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Atrial fibrillation (AF) is the most common cardiac arrhythmia world-
wide, afflicting an estimated 33 million people.1 In the United States 
alone, AF- related annual cost estimates are as high as $26 billion. 
While some patients experience bothersome symptoms, many remain 
completely asymptomatic. Most concerning is the severe consequence 
of untreated AF. Patients with AF are at an increased risk of stroke and 
systemic embolism, up to 15% per year.2 In the United States, 800 000 
people suffer a stroke annually, and these strokes cause one in every 
20 deaths.1 This converts to one stroke every 40 seconds and one 
stroke- related death every 4 minutes.
Despite these staggering statistics, there has long been anecdotal 
evidence that most of the at- risk population is unaware of AF or its 
association with stroke risk. In fact, prior studies have suggested that 
public screening of adults ages 65 and older would identify one new 
diagnosis of AF for every 170 adults screened.1 Additionally, inade-
quate understanding of how AF can cause stroke may contribute to 
the underutilization of, poor adherence to, and frequent early dis-
continuation of stroke preventative medications (eg, anticoagulants) 
among AF patients.3
To better understand the global awareness of AF, Wendelboe and 
colleagues conducted a global survey to quantify public awareness of 
AF in comparison to other thrombotic and non- thrombotic illnesses.4 
Unsurprisingly, they found less than half (48%) of those surveyed were 
aware of AF. This differed considerably from the high awareness of 
heart attacks (74%), stroke (81%), human immunodeficiency/acquired 
immunodeficiency syndrome (HIV/AIDS; 80%), breast cancer (81%), 
and prostate cancer (78%). Additionally, they found a striking differ-
ence in awareness by country, with Uganda reporting the highest 
awareness (69%) and Canada the lowest (25%). While differences in 
the surveyed population and potential selection/responder bias may 
have contributed to part of the variation, a nearly three- fold difference 
is hard to ignore.
Perhaps the most important finding from this report is that only 
36% of respondents were aware that AF can lead to stroke. With 
such prominent morbidity and mortality associated with stroke and 
the presence of a highly effective prevention method (anticoagu-
lation), one would hope that the awareness of this connection was 
higher.
To help contextualize, the World Health Organization estimates 
2.1 million global cases of HIV with one million yearly deaths.5 They 
also estimate annual deaths due to breast cancer around 500 000 
globally while the World Cancer Research Fund estimates 1.1 million 
global cases of prostate cancer annually. Each are incredibly important 
diseases worthy of robust public awareness campaigns. So too is AF, 
for which millions of people worldwide are at high risk of a potentially 
devastating stroke. Nonetheless, awareness of these conditions was 
strikingly higher than AF in this survey.
The role that advocacy organizations play in public aware-
ness should not be underestimated. In fact, the World Health 
Organization has identified nine global public health days to raise 
awareness of HIV/AIDS, tobacco use, tuberculosis, and malaria. 
However, they do not have a day associated with AF, despite its 
sizeable prevalence and potentially devastating morbidity and mor-
tality. Other well- funded and well- organized movements focused 
solely on HIV/AIDS and specific cancer types (eg, breast and pros-
tate). It is no wonder that these conditions have gained widespread 
awareness across the globe. For the cardiovascular conditions, many 
major organizations (eg,the American Heart Association/American 
Stroke Association and the European Society of Cardiology) have 
focused on risk factor and lifestyle modification in their public 
health awareness campaigns. Additionally, these major cardiovas-
cular organizations cover a wide range of diseases, from coronary 
artery disease and stroke to sudden cardiac death and atrial fibrilla-
tion. This diversity may limit the awareness of any specific disease, 
such as atrial fibrillation.
To help address a public knowledge gap regarding thrombosis, the 
International Society on Thrombosis and Haemostasis began World 
Thrombosis Day in 2014.6 This effort, in partnership with a number of 
other thrombosis- related organizations, focuses on public awareness 
of thrombotic disorders, primarily venous thromboembolism and AF. 
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To maximize the effect, the organizers have made two key strategic 
decisions.
First, World Thrombosis Day has chosen a multi- lateral approach 
to their awareness campaign. The have different events focused on 
public and professional awareness. They also use a variety of meth-
ods to spread their message, include social media, traditional media, 
and various in- person events. Other advocacy organizations, such as 
StopAfib.org also have a strong online presence to provide vital infor-
mation to the public and to provide a community for patients and their 
family members. This type of approach is critical for reaching global 
audiences in a cost- conscious manner.
Second, World Thrombosis Day organizers have chosen to partner 
with local organizations to facilitate the activities of local organiza-
tions. This minimizes the burden on the primary organizing committee, 
engages more participants, and allows for better personalization based 
on the needs of individual communities and countries. It also allows 
for individual organizations to develop new and creative events that 
can be adapted and replicated broadly in subsequent years. For ex-
ample, in October 2017, a World Thrombosis Day breakfast and walk 
occurred outside the Sydney International Convention Center while a 
Dog Parade was held in Mexico to promote walking as a thrombosis 
preventative (and treatment) strategy.
World Thrombosis Day has maintained a greater focus on venous 
thrombosis rather than AF awareness. This may reflect the interest of 
its originating organization, the International Society on Thrombosis 
and Haemostasis. It may also reflect a purposeful strategy to start with 
one clear focus and then slowly grow and expand into AF awareness 
over time. Either way, Wendelboe and colleagues highlight the desper-
ate need for improved AF awareness worldwide.
These survey data will serve as an excellent baseline for measur-
ing the impact of various public awareness campaigns, such as World 
Thrombosis Day. Yet, as important as measures of public awareness are, 
they are not the ultimate goal. Instead, our focus must be on increas-
ing the use of preventative treatments as a means of reducing stroke. 
Improved rates of detecting AF and initiating stroke- preventative 
treatments are key metrics. The link between public awareness and 
these measures remains logical but without a strong evidence base. 
Nonetheless, the efforts are a critical component of achieving the ulti-
mate goal (stroke reduction) and worthy of global support.
The National Heart, Lung, and Blood Institute at the United 
States National Institutes of Health recently published a clinical 
practice guideline on implementation strategies for clinical practice 
guidelines.7 That report outlines a multi- level framework involving a 
policy level, clinical institution levels, provider level, and patient level. 
Within the patient level is an assessment of knowledge, which is di-
rectly impacted by health awareness campaigns. However, equally 
important is the provider level use of screening and diagnosis along 
with treatment and procedural decision making. The framework 
also highlights the important role of institutions to support educa-
tional outreach and clinical decision support. The survey data from 
Wendelboe and colleagues would suggest that educational outreach 
must extend beyond provider education to also include educating 
the public.7
To achieve the goal of reduced AF- related stroke burden we must 
target preventative and therapeutic strategies in addition to awareness. 
For example, we must encourage efforts to reduce the development of 
AF, such as increasing physical activity, weight loss, and treatment of 
comorbid illnesses (patient and policy levels). The public lexicon should 
include “AFib” just as easily as it does “heart attack,” “stroke,” and “can-
cer.” We also need to address issues surrounding medication prescrib-
ing, access, adherence, and persistence (patient, provider, institutional, 
and policy levels). These will require multifaceted efforts to develop, 
test, implement, and promote care programs. Public health and gov-
ernmental organizations, pharmaceutical companies, insurers and other 
payers, professional societies and advocacy organizations, healthcare 
providers, and patients all must work together to increase the use of 
stroke- preventative treatment strategies among patients with atrial 
fibrillation.
Together, we can make important strides in both public awareness 
of AF and the use of stroke- preventative measures. With regards to 
public awareness, we now have our starting point. How we reach our 
ultimate goal remains an exciting and uncharted journey.
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